Sophia

SOPHiA GENETICS Reports Financial Results for the Third Quarter of Fiscal 2023

Retrieved on: 
Tuesday, November 7, 2023
Average cost, AstraZeneca, Operating cost, Book of Wisdom, MSK, Organization, Sophia Genetics, CLB, Growth, Central European Time, COVID, Sophia, Neoplasm, COVID-19, Health equity, Marketing, Partnership, Forecasting, Liquid biopsy, Integration, Constant, Eastern Time Zone, GENETICS, Pharmaceutical industry, Video game, Medical imaging

BOSTON and ROLLE, Switzerland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • BOSTON and ROLLE, Switzerland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today reported financial results for the third quarter ended September 30, 2023.
  • Cash burn for the third quarter of 2023 was $15.8 million, compared to $27.4 million in the third quarter of 2022.
  • R&D expenses for the third quarter of 2023 were $9.0 million compared to $10.1 million for the third quarter of 2022.
  • SOPHiA GENETICS will host a conference call and live webcast to discuss the third quarter of 2023 financial results as well as business outlook on Tuesday, November 7, 2023, at 8:00 a.m. (08:00) Eastern Time / 2:00 p.m. (14:00) Central European Time.

BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™

Retrieved on: 
Tuesday, November 7, 2023
Urology, Health, Biomarker, Sophia Genetics, MSK, Artificial intelligence, Database, Sophia, Clinical trial, Memorial Sloan Kettering Cancer Center, Cancer, Risk assessment, Algorithm, OPKO Health, Liquid biopsy, Patient, GENETICS, Medical imaging

BOSTON and ELMWOOD PARK, N.J. and ROLLE, Switzerland, Nov. 7, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that BioReference® Health, LLC, an OPKO Health, Inc. company and full-service laboratory that processes more than 12 million tests annually, will implement SOPHiA GENETICS' technology and add MSK-ACCESS® liquid biopsy to its test suite. With the implementation of SOPHiA GENETICS, BioReference will be the first laboratory globally to adopt MSK-ACCESS® powered with SOPHiA DDM™. The offering will be commercially available for ordering by healthcare providers through BioReference, and its specialty division, GenPath® Oncology in 2024.

Key Points: 
  • With the implementation of SOPHiA GENETICS, BioReference will be the first laboratory globally to adopt MSK-ACCESS® powered with SOPHiA DDM™.
  • The offering will be commercially available for ordering by healthcare providers through BioReference, and its specialty division, GenPath® Oncology in 2024.
  • BioReference® Health will implement SOPHiA GENETICS' technology and add MSK-ACCESS® liquid biopsy to its test suite.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on X (formerly known as Twitter), LinkedIn , Facebook , and Instagram .

BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™

Retrieved on: 
Tuesday, November 7, 2023
Urology, Health, Biomarker, Sophia Genetics, MSK, Artificial intelligence, Database, Sophia, Clinical trial, Memorial Sloan Kettering Cancer Center, Cancer, Risk assessment, Algorithm, OPKO Health, Liquid biopsy, Patient, GENETICS, Medical imaging

BOSTON and ELMWOOD PARK, N.J., and ROLLE, Switzerland, Nov. 7, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that BioReference® Health, LLC, an OPKO Health, Inc. company and full-service laboratory that processes more than 12 million tests annually, will implement SOPHiA GENETICS' technology and add MSK-ACCESS® liquid biopsy to its test suite. With the implementation of SOPHiA GENETICS, BioReference will be the first laboratory globally to adopt MSK-ACCESS® powered with SOPHiA DDM™. The offering will be commercially available for ordering by healthcare providers through BioReference, and its specialty division, GenPath® Oncology in 2024.

Key Points: 
  • With the implementation of SOPHiA GENETICS, BioReference will be the first laboratory globally to adopt MSK-ACCESS® powered with SOPHiA DDM™.
  • The offering will be commercially available for ordering by healthcare providers through BioReference, and its specialty division, GenPath® Oncology in 2024.
  • MSK-ACCESS® powered with SOPHiA DDM™ is being designed to align with the most up-to-date guidelines and clinical trial data, reflecting major biologically actionable biomarkers.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on X , LinkedIn , Facebook , and Instagram .

SOPHiA GENETICS to Announce Financial Results for the Third Quarter of Fiscal 2023 on November 7, 2023

Retrieved on: 
Tuesday, October 24, 2023
Sophia, CEST, GENETICS, Pharmaceutical industry, Financial adviser

BOSTON and GENEVA, Switzerland, Oct. 24, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the third quarter of fiscal 2023 before U.S. markets open on Tuesday, November 7, 2023.

Key Points: 
  • BOSTON and GENEVA, Switzerland, Oct. 24, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the third quarter of fiscal 2023 before U.S. markets open on Tuesday, November 7, 2023.
  • On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EST / 2:00 p.m. (14:00) CEST.
  • The call will be webcast live on the SOPHiA GENETICS Investor Relations website .
  • Additionally, a replay will be available on the website after its completion.

First Production Well Installed at HMN Li Project

Retrieved on: 
Wednesday, October 25, 2023
Lithium, Water, Technische Universität Darmstadt, Sophia, RFQ, VES, Vertical electrical sounding

VANCOUVER, BC, Oct. 25, 2023 /PRNewswire/ -- Lithium South Development Corporation (the "Company") (TSX-V: LIS) (OTCQB: LISMF) (Frankfurt: OGPQ) is pleased to report that the first production well at the HMN Li Project, located in Salta Province, Argentina, has been installed.

Key Points: 
  • VANCOUVER, BC, Oct. 25, 2023 /PRNewswire/ -- Lithium South Development Corporation (the "Company") (TSX-V: LIS) (OTCQB: LISMF) (Frankfurt: OGPQ) is pleased to report that the first production well at the HMN Li Project, located in Salta Province, Argentina, has been installed.
  • The well has been drilled to a depth of 60 meters and is now being cased and screened.
  • The Company is issuing a Request for Quotation (RFQ) for the exploration of the Sophia II and Sophia III claim blocks.
  • Located approximately 10 kilometers north of the HMN Li Project area, the claim group is in close proximity to any future lithium production development.

First Production Well Installed at HMN Li Project

Retrieved on: 
Wednesday, October 25, 2023
Lithium, Water, Technische Universität Darmstadt, Sophia, RFQ, VES, Vertical electrical sounding

VANCOUVER, BC, Oct. 25, 2023 /PRNewswire/ -- Lithium South Development Corporation (the "Company") (TSX-V: LIS) (OTCQB: LISMF) (Frankfurt: OGPQ) is pleased to report that the first production well at the HMN Li Project, located in Salta Province, Argentina, has been installed.

Key Points: 
  • VANCOUVER, BC, Oct. 25, 2023 /PRNewswire/ -- Lithium South Development Corporation (the "Company") (TSX-V: LIS) (OTCQB: LISMF) (Frankfurt: OGPQ) is pleased to report that the first production well at the HMN Li Project, located in Salta Province, Argentina, has been installed.
  • The well has been drilled to a depth of 60 meters and is now being cased and screened.
  • The Company is issuing a Request for Quotation (RFQ) for the exploration of the Sophia II and Sophia III claim blocks.
  • Located approximately 10 kilometers north of the HMN Li Project area, the claim group is in close proximity to any future lithium production development.

SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care

Retrieved on: 
Wednesday, October 18, 2023
Memorial Sloan Kettering Cancer Center, AstraZeneca, MPH, Sophia Genetics, Physician, Data, MSK, Organization, Research, Artificial intelligence, Disease, Sophia, Health equity, Partnership, Algorithm, Cancer, Patient, Death, GENETICS, Pharmaceutical industry, Medical imaging, MD

BOSTON and ROLLE, Switzerland, Oct. 18, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a category-defining software company and a global leader in data-driven medicine today announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK), a top cancer treatment and research institution, and AstraZeneca (LSE/STO/Nasdaq: AZN) to bring high quality, comprehensive cancer testing to a global scale. With this collaboration, the three leading organizations will further their shared goal to advance health equity on a global scale by providing inclusive access to comprehensive cancer testing worldwide. 

Key Points: 
  • With this collaboration, the three leading organizations will further their shared goal to advance health equity on a global scale by providing inclusive access to comprehensive cancer testing worldwide.
  • Through the newly announced partnership, SOPHiA GENETICS, MSK, and AstraZeneca will create a decentralized global network for cancer testing, including underserved regions where access to testing remains scarce.
  • "We believe that this collaboration will enable patients from around the world to better understand the genomic profile of their cancer.
  • Broad access to quality testing can vastly improve cancer diagnosis and physicians' treatment decisions," said Kristina Rodnikova, Head of Global Oncology Diagnostics, AstraZeneca.

SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care

Retrieved on: 
Wednesday, October 18, 2023
Memorial Sloan Kettering Cancer Center, AstraZeneca, MPH, Sophia Genetics, Physician, Data, MSK, Organization, Research, Artificial intelligence, Disease, Sophia, Health equity, Partnership, Algorithm, Cancer, Patient, Death, GENETICS, Pharmaceutical industry, Medical imaging, MD

BOSTON and ROLLE, Switzerland, Oct. 18, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a category-defining software company and a global leader in data-driven medicine today announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK), a top cancer treatment and research institution, and AstraZeneca (LSE/STO/Nasdaq: AZN) to bring high quality, comprehensive cancer testing to a global scale. With this collaboration, the three leading organizations will further their shared goal to advance health equity on a global scale by providing inclusive access to comprehensive cancer testing worldwide. 

Key Points: 
  • With this collaboration, the three leading organizations will further their shared goal to advance health equity on a global scale by providing inclusive access to comprehensive cancer testing worldwide.
  • Through the newly announced partnership, SOPHiA GENETICS, MSK, and AstraZeneca will create a decentralized global network for cancer testing, including underserved regions where access to testing remains scarce.
  • "We believe that this collaboration will enable patients from around the world to better understand the genomic profile of their cancer.
  • Broad access to quality testing can vastly improve cancer diagnosis and physicians' treatment decisions," said Kristina Rodnikova, Head of Global Oncology Diagnostics, AstraZeneca.

Start-ups from across the globe look to woo investors with transformational tech shifts at world's largest start-up event in Dubai

Retrieved on: 
Thursday, October 12, 2023
Carbon, Anandan, IP, Food, Peak, All India Central Council of Trade Unions, Acquisition, Female, Tutti frutti, AI, Molecular machine, Digital economy, Sony, GITEX, Sophia, Mount Everest, Adventure, VR2, Ecosystem, Comprehensive economic partnership agreement, Comprehensive Economic Partnership Agreement between India and South Korea, Marketing, Protein, Dubai World Trade Centre, Dubai Chamber of Commerce and Industry, Ola Cabs, Capital, De Carbon, Meat, PlayStation, Drug, Video game, Cryptocurrency, Film industry

DUBAI, UAE, Oct. 12, 2023 /PRNewswire/ -- India's burgeoning entrepreneurial spirit and proliferation of next-gen deep tech talent will take centre-stage next week in Dubai, as the world's largest start-up event prepares to host the biggest showcase of Indian start-ups ever seen outside the south-central Asian nation.

Key Points: 
  • We are bridging the gap with a solution, and there's a humongous untapped economic value in this waste.
  • According to Dubai Chambers, 30 percent of the emirate's start-ups are Indian-owned, while 83,000 Indian companies are registered in Dubai.
  • Expand North Star is the powerhouse start-up event inspired by GITEX GLOBAL, the world's largest tech show, which takes place from 16-20 October at the Dubai World Trade Centre (DWTC).
  • The blockbuster duo, organised by DWTC, are spearheading the world's biggest tech takeover in Dubai, spanning 2.7 million sq.

Start-ups from across the globe look to woo investors with transformational tech shifts at world's largest start-up event in Dubai

Retrieved on: 
Thursday, October 12, 2023
Carbon, Anandan, IP, Food, Peak, All India Central Council of Trade Unions, Acquisition, Female, Tutti frutti, AI, Molecular machine, Digital economy, Sony, GITEX, Sophia, Mount Everest, Adventure, VR2, Ecosystem, Comprehensive economic partnership agreement, Comprehensive Economic Partnership Agreement between India and South Korea, Marketing, Protein, Dubai World Trade Centre, Dubai Chamber of Commerce and Industry, Ola Cabs, Capital, De Carbon, Meat, PlayStation, Drug, Video game, Cryptocurrency, Film industry

DUBAI, UAE, Oct. 12, 2023 /PRNewswire/ -- India's burgeoning entrepreneurial spirit and proliferation of next-gen deep tech talent will take centre-stage next week in Dubai, as the world's largest start-up event prepares to host the biggest showcase of Indian start-ups ever seen outside the south-central Asian nation. 

Key Points: 
  • We are bridging the gap with a solution, and there's a humongous untapped economic value in this waste.
  • According to Dubai Chambers, 30 percent of the emirate's start-ups are Indian-owned, while 83,000 Indian companies are registered in Dubai.
  • Expand North Star is the powerhouse start-up event inspired by GITEX GLOBAL, the world's largest tech show, which takes place from 16-20 October at the Dubai World Trade Centre (DWTC).
  • The blockbuster duo, organised by DWTC, are spearheading the world's biggest tech takeover in Dubai, spanning 2.7 million sq.